Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/PF-4455242> ?p ?o }
Showing triples 1 to 67 of
67
with 100 triples per page.
- PF-4455242 abstract "PF-4455242 is a selective, short-acting (non-\"inactivating\") antagonist of the κ-opioid receptor. Discovered by Pfizer in 2009, it was pursued in a phase I clinical trial for the treatment of bipolar disorder, and was also investigated as a treatment for depression and substance abuse. However, development was stopped in September 2010 due to toxicology findings in animals that had been exposed to the drug for three months.".
- PF-4455242 atcPrefix "None".
- PF-4455242 casNumber "1202647-54-8".
- PF-4455242 iupacName "2-Methyl-N-{[2’-(1-pyrrolidinylsulfonyl)-4-biphenylyl]methyl}-1-propanamine".
- PF-4455242 pubchem "44599828".
- PF-4455242 thumbnail PF-4455242.svg?width=300.
- PF-4455242 wikiPageID "43221737".
- PF-4455242 wikiPageLength "3774".
- PF-4455242 wikiPageOutDegree "17".
- PF-4455242 wikiPageRevisionID "699727126".
- PF-4455242 wikiPageWikiLink Bipolar_disorder.
- PF-4455242 wikiPageWikiLink samidorphan.
- PF-4455242 wikiPageWikiLink CERC-501.
- PF-4455242 wikiPageWikiLink Category:Amines.
- PF-4455242 wikiPageWikiLink Category:Kappa_antagonists.
- PF-4455242 wikiPageWikiLink Category:Pyrrolidines.
- PF-4455242 wikiPageWikiLink Category:Sulfones.
- PF-4455242 wikiPageWikiLink Clinical_trial.
- PF-4455242 wikiPageWikiLink Depression_(mood).
- PF-4455242 wikiPageWikiLink JDTic.
- PF-4455242 wikiPageWikiLink Oral_administration.
- PF-4455242 wikiPageWikiLink Pfizer.
- PF-4455242 wikiPageWikiLink Phase_1.
- PF-4455242 wikiPageWikiLink Receptor_antagonist.
- PF-4455242 wikiPageWikiLink Substance_abuse.
- PF-4455242 wikiPageWikiLink Toxicology.
- PF-4455242 wikiPageWikiLink Κ-opioid_receptor.
- PF-4455242 wikiPageWikiLinkText "PF-4455242".
- PF-4455242 atcPrefix "None".
- PF-4455242 c "21".
- PF-4455242 casNumber "1202647".
- PF-4455242 chemspiderid "26610764".
- PF-4455242 h "28".
- PF-4455242 inchi "1".
- PF-4455242 inchikey "OWVIKBRKPCTDEP-UHFFFAOYAG".
- PF-4455242 iupacName "2".
- PF-4455242 molecularWeight "372.524".
- PF-4455242 n "2".
- PF-4455242 o "2".
- PF-4455242 pubchem "44599828".
- PF-4455242 routesOfAdministration Oral_administration.
- PF-4455242 s "1".
- PF-4455242 smiles "CCCNCC1=CC=CC2=CC=CC=C2SN3CCCC3".
- PF-4455242 stdinchi "1".
- PF-4455242 stdinchikey "OWVIKBRKPCTDEP-UHFFFAOYSA-N".
- PF-4455242 wikiPageUsesTemplate Template:Drugbox.
- PF-4455242 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- PF-4455242 wikiPageUsesTemplate Template:Opioidergics.
- PF-4455242 wikiPageUsesTemplate Template:Reflist.
- PF-4455242 subject Category:Amines.
- PF-4455242 subject Category:Kappa_antagonists.
- PF-4455242 subject Category:Pyrrolidines.
- PF-4455242 subject Category:Sulfones.
- PF-4455242 hypernym Antagonist.
- PF-4455242 type ChemicalSubstance.
- PF-4455242 type Drug.
- PF-4455242 type ChemicalObject.
- PF-4455242 type Thing.
- PF-4455242 type Q8386.
- PF-4455242 comment "PF-4455242 is a selective, short-acting (non-\"inactivating\") antagonist of the κ-opioid receptor. Discovered by Pfizer in 2009, it was pursued in a phase I clinical trial for the treatment of bipolar disorder, and was also investigated as a treatment for depression and substance abuse. However, development was stopped in September 2010 due to toxicology findings in animals that had been exposed to the drug for three months.".
- PF-4455242 label "PF-4455242".
- PF-4455242 sameAs Q18359213.
- PF-4455242 sameAs m.0114m34k.
- PF-4455242 sameAs Q18359213.
- PF-4455242 wasDerivedFrom PF-4455242?oldid=699727126.
- PF-4455242 depiction PF-4455242.svg.
- PF-4455242 isPrimaryTopicOf PF-4455242.